Nitrogen Containing Reactant Patents (Class 530/405)
  • Patent number: 10786561
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 10A and 39, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: September 29, 2020
    Assignee: Pfizer Inc.
    Inventors: Fiona Laichu Lin, Viliam Pavliak, Michael William Pride, Shite Sebastian
  • Patent number: 9561264
    Abstract: The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: February 7, 2017
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Markus H. Frank, Mohamed H. Sayegh
  • Patent number: 9315556
    Abstract: The present invention is directed to a polypeptide which comprises: (i) an Rv1753c protein sequence; (ii) a variant of an Rv1753c protein sequence; or (iii) an immunogenic fragment of an Rv1753c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: April 19, 2016
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: James Brown, Pascal Mettens, Dennis Murphy
  • Patent number: 9216223
    Abstract: The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: December 22, 2015
    Assignee: President and Fellows of Harvard College
    Inventor: John J. Mekalanos
  • Publication number: 20150125423
    Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 7, 2015
    Inventors: Jennifer Mitcham, Matthew Moyle
  • Patent number: 9005910
    Abstract: The purpose is to produce, with high reproducibility, a complex of labeled probes and a carrier, said complex being to be used for detecting and measuring a target substance to be measured with high sensitivity and high stability. The means for accomplishing the purpose is that a label is bound to a probe-water soluble carrier conjugate using specific binding of an avidin compound such as avidin, streptavidin, etc. to biotin, and the binding of the avidin compound to the probe is performed before the binding to the carrier. Namely, after conjugating the avidin compound to a substance which is capable of binding to the target substance, the conjugate is bound to a high-molecule water-soluble carrier to produce a complex of the avidinized probes and the water-soluble carrier. Then the complex of the avidinized probes and the water-soluble carrier is mixed with a biotinylated label.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: April 14, 2015
    Assignees: Eiken Kagaku Kabushiki Kaisha, Advanced Life Science Institute, Inc.
    Inventors: Yoshiyuki Ohiro, Susumu Takayasu
  • Publication number: 20150072894
    Abstract: The invention provides a novel class of cyanine dyes that are functionalized with sulfonic acid groups and a linker moiety that facilitates their conjugation to other species and substituent groups which increase the water-solubility, and optimize the optical properties of the dyes. Also provided are conjugates of the dyes, methods of using the dyes and their conjugates and kits including the dyes and their conjugates.
    Type: Application
    Filed: September 17, 2014
    Publication date: March 12, 2015
    Applicant: Pacific Biosciences of California, Inc.
    Inventors: Stephen YUE, Gene SHEN, Wei-Chuan (David) SUN
  • Publication number: 20150064212
    Abstract: Provided are bivalent immunogenic composition against morphine-heroin addiction comprising a carrier protein (“CP”) and a morphinic product, wherein the CP and the morphinic product are connected by a spacer-linker arm having a total molecular size of 16-21 ?, and methods of using the same.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 5, 2015
    Inventors: Benito Anton PALMA, Philippe Leff GELMAN
  • Publication number: 20150050314
    Abstract: Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against Plasmodium falciparum, the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine against Plasmodium vivax are also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.
    Type: Application
    Filed: October 29, 2014
    Publication date: February 19, 2015
    Applicant: The United States of America as represented by the Secretary, Department of Health and Human Service
    Inventors: Rachel Schneerson, Joanna Kubler-Kielb, Yimin Wu, Louis Miller, Fathy Majadly, John B. Robbins
  • Publication number: 20140348865
    Abstract: Disclosed are HIV immunogens. Also disclosed are nucleic acids encoding these immunogens and methods of producing these antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject.
    Type: Application
    Filed: September 7, 2012
    Publication date: November 27, 2014
    Inventors: Peter Kwong, Jason McLellan, Marie Pancera, Jason Gorman, Mallika Sastry, Kaifan Dai, Tongqing Zhou, John Mascola, Gary Nabel, Masaru Kanekiyo, Yongping Yang, Jiang Zhu, Lai-Xi Wang, William Schief, Chris Carrico, Mohammed Amin
  • Publication number: 20140341939
    Abstract: The present invention provides a tumor antigen-specific Th-inducing polypeptide capable of efficient antigen presentation, and an antitumor agent using same.
    Type: Application
    Filed: December 14, 2012
    Publication date: November 20, 2014
    Inventor: Keiko Udaka
  • Patent number: 8858955
    Abstract: The present application discloses a method for making an immunogenic composition comprising an improved way of conducting saccharide-protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. In addition, the conjugate is mixed with a staphylococcal antigen. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed.
    Type: Grant
    Filed: January 2, 2008
    Date of Patent: October 14, 2014
    Assignee: GlaxoSmithKline Biologicals s.a.
    Inventors: Ralph Leon Biemans, Pierre Duvivier
  • Patent number: 8841249
    Abstract: The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: September 23, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Nils Langeland Johansen, Henrik Sune Andersen, Jens Buchardt, Leif Norskov-Lauritsen
  • Patent number: 8772048
    Abstract: Fluorophores derived from photoactivatable azide-pi-acceptor fluorogens or from a thermal reaction of an azide-pi-acceptor fluorogen with an alkene or alkyne are disclosed. Fluorophores derived from a thermal reaction of an alkyne-pi-acceptor fluorogen with an azide are also disclosed. The fluorophores can readily be activated by light and can be used to label a biomolecule and imaged on a single-molecule level in living cells.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: July 8, 2014
    Assignees: Kent State University, Leland Stanford Junior University
    Inventors: Robert J. Twieg, William E. Moerner, Samuel J. Lord, Na Liu, Reichel Samuel
  • Patent number: 8772446
    Abstract: A bifunctional chelating agent of the formula (I): wherein the variables R1, R1?, Q1, Q2 and M are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a stable or radioactive metal; a conjugate of the complex covalently attached to a biological carrier; and a pharmaceutical composition containing the conjugate.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: July 8, 2014
    Assignee: Nordion (Canada) Inc.
    Inventors: Mike Adam, Eszter Boros, Cara L. Ferreira, Chris Orvig, Eric William Price
  • Publication number: 20140170151
    Abstract: The present invention synthetic oligo-?-(1?6)-glucosamine structures and a methodology which essentially allows for the synthesis of any oligo-?-(1?6)-glucosamine species having a definite number of monosaccharide units, including a set pattern of acetylated and non-acetylated residues. The invention further provides antibodies to these synthetic oligo-?-(1?6)-glucosamines as well as compositions thereof and methods for treating and preventing infections caused by bacteria expressing poly-?-(1?6)-glucosamines, such as Staphylococcus aureus.
    Type: Application
    Filed: February 11, 2014
    Publication date: June 19, 2014
    Inventors: A. Stewart CAMPBELL, Obadiah J. PLANTE
  • Patent number: 8753623
    Abstract: The present invention discloses isolated peptides encoding an antigen or fragments thereof from the N-terminus of hemagglutinin protein of influenza, methods for isolating such antigens and specific uses thereof. The peptide can be used as a vaccine to generate an antibody response that neutralizes influenza infectivity against a variety of influenza strains.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: June 17, 2014
    Inventors: Runtao He, Xuguang Li, Gary Van Domselaar
  • Publication number: 20140141034
    Abstract: A process is provided for preparing a conjugate of Formula (I-A) or (I) comprising a polypeptide containing n number of tyrosine units, where n is an integer greater than or equal to 1, dispersed within the amino acid chain having and amino terminus end (A1) and an acid terminus end (A2) of the protein or polypeptide and having a weight average molecular weight equal to or greater than 10,000 Daltons (10 kDa), wherein the conjugate comprises a number m of tyrosine conjugates (modified tyrosine residues) as depicted in Formula (I-A) or (I), where m is at least one and is less than or equal to n: where X, Lg, L and R are as defined herein.
    Type: Application
    Filed: July 5, 2012
    Publication date: May 22, 2014
    Applicant: NOVARTIS AG
    Inventors: Roberto Adamo, Martin Allen, Francesco Berti, Elisa Danieli, Qi-Ying Hu
  • Publication number: 20140141004
    Abstract: Disclosed are immunogenic peptides, related fusion proteins, nucleic acids encoding the peptides or fusion proteins, conjugates, expression vectors, host cells, and antibodies. Also, disclosed are pharmaceutical compositions, vaccines for use in the treatment or prevention of cancer, e.g., alveolar rhabodomyosarcoma, methods of stimulating a T cell to kill a tumor cell, methods of stimulating CD4+ and CD8+ T cells, and methods of treating or preventing cancer are further provided herein.
    Type: Application
    Filed: December 20, 2013
    Publication date: May 22, 2014
    Applicant: The U.S.A as represented by the Secretary, Department of Health and Human Services
    Inventors: Jay A. Berzofsky, Leon T. van den Broeke, Crystal L. Mackall, Lee J. Helman
  • Patent number: 8716033
    Abstract: The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to modified oligosaccharides. The invention further relates to kits that may be used to produce the antibodies of the invention.
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: May 6, 2014
    Assignee: Life Technologies Corporation
    Inventors: Brian Agnew, Schuyler B. Corry, Kyle R. Gee
  • Patent number: 8709830
    Abstract: The present invention provides methods, compositions, and kits useful in preparing labeled molecules, which are useful in the detection of binding partners.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: April 29, 2014
    Assignee: Biotium, Inc.
    Inventors: Fei Mao, Wai-Yee Leung, Ching-Ying Cheung, Hye Eun Hoover
  • Patent number: 8673652
    Abstract: The immunoassay method and kit are provided for the detection and/or the determination of zolpidem. The disclosure provides novel antibodies, derived from a novel immunogen, that are highly sensitive and bind to zolpidem and its main urinary metabolite [3-(2-N,N-dimethylamino-2-oxoethyl)-6-methylimidazo[1,2-a]pyridin-2-yl]benzoic acid, enabling an extension of the detection window of zolpidem in individuals who have abused the drug, or have been victim of its side-effects or its criminal misuse.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: March 18, 2014
    Assignee: Randox Laboratories Limited
    Inventors: Stephen Peter Fitzgerald, Robert Ivan McConnell, Philip Andrew Lowry, Elouard Benchikh
  • Patent number: 8669046
    Abstract: Antibodies that specifically bind to a peptide having an amino acid sequence as found at the N-terminus of the HA2 fusion peptide of the influenza A virus may be raised by inoculating a mammal with a conjugate of the peptide. In one embodiment, the conjugate comprises the peptide linked to a spacer (e.g. 6-aminocaproic acid) and a carrier protein (e.g. KLH). The antibodies may be used as a universal reagent for detecting HA proteins of influenza viruses. The antibodies are useful as versatile reagents for laboratory research and vaccine potency determination, especially in the event of pandemic influenza outbreaks.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: March 11, 2014
    Inventors: Xuguang (Sean) Li, Runtao He, Gary Van Domselaar
  • Patent number: 8658433
    Abstract: Novel azo, azide, and sulfenate photoactive compounds and methods using the compounds for photodiagnostic and/or phototherapeutic procedures. The compounds have the formula E-L-DYE-X—Y, wherein DYE is a photoactive component comprising a photoactive diagnostic agent, a photoactive type 1 agent, a photoactive type 2 agent, or a combination thereof; Y is a photoactive component comprising a photoactive type 1 agent, a photoactive type 2 agent, or a combination thereof; E is a targeting component for targeting the compound to an anatomical and/or physiological site of a patient; L is a linking component for linking E to DYE; and X is a linking component for linking DYE to Y.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: February 25, 2014
    Assignee: Mallinckrodt LLC
    Inventors: Raghavan Rajagopalan, Gary L. Cantrell, Samuel I. Achilefu, Joseph E. Bugaj, Richard B. Dorshow
  • Publication number: 20140024056
    Abstract: The present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and/or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins. The surrogate compounds of the invention typically comprise antigenic epitopes (one of which carries a post-translational modification) that are tethered by a flexible and hydrophilic linker. The resulting compound behaves like a surrogate of the post-translationally modified protein because it preserves the character of the included antigens and allows recognition by specific antibodies targeting the individual antigens.
    Type: Application
    Filed: February 10, 2012
    Publication date: January 23, 2014
    Applicant: President and Fellows of Harvard College
    Inventors: Michael Chorev, Joes A. Halperin
  • Publication number: 20140017269
    Abstract: Genes for proteins which spontaneously form dimers and/or oligomers can be recombinantly linked together, which upon expression in E. coli produces stable dimeric fusion proteins that spontaneously self-assemble into enormous, polyvalent complexes having increased immunogenicity and functionality. Linear, network and agglomerate complexes with enormous sizes and polyvalences are constructed using glutathione S-transferase, Norovirus P domains (NoV P? and NoV+), the protruding (P) domain of hepatitis E virus (HEV P), the astrovirus P domain (AstV), a monomeric peptide epitope (M2e of influenza virus), and/or a protein antigen (VP8* of rotavirus) fused in different combinations. The resulting complexes can contain hundreds to thousands NoV P-protein, HEV, AstV, M2e and/or VP8* copies and exhibit higher immunogenicity than the individual proteins alone.
    Type: Application
    Filed: March 14, 2013
    Publication date: January 16, 2014
    Inventors: Ming TAN, Xi Jiang, Leyi Wang
  • Publication number: 20130330414
    Abstract: This disclosure provides therapeutic compositions and methods for inducing an anti-inflammatory response and/or treating inflammation in the gastrointestinal tract and/or accumulating gut microbial antigen-specific anti-inflammatory T cells in a patient in need thereof.
    Type: Application
    Filed: March 15, 2013
    Publication date: December 12, 2013
    Applicant: UTI Limited Partnership
    Inventor: Pedro Santamaria
  • Publication number: 20130315920
    Abstract: A complex comprising a Class II HLA-DRB1*03 or Class II HLA-DRB1*13 molecule bound to a peptide, wherein the peptide comprises the amino acid sequence HTYTIDWTKDAVTWS or a portion thereof, or a variant of the given amino acid sequence or portion wherein the side chains of one or two or three or four or five or six or seven of the amino acid residues are altered, wherein the peptide comprising the portion, or variant, is capable of binding HLA-DRB1*03 and/or HLA-DRB1*13. The complex may be used to select Aspergillus and Candida antigen-specific T cells.
    Type: Application
    Filed: November 16, 2011
    Publication date: November 28, 2013
    Applicant: Cell Medica Limited
    Inventors: Max S. Topp, Claudia Stuehler, Nina Khanna
  • Patent number: 8592564
    Abstract: Generally, the present invention relates to lamotrigine analogs that have substituents at the triazine 3-position and on the benzene 4-position and 5-position. The lamotrigine analogs can include immunogenic moieties that can be used to prepare anti-lamotrigine antibodies, or antigenic moieties that can be used in immunodiagnostic assays for lamotrigine. Also, the lamotrigine analog can include tracer moieties for detecting the presence or amount of the analog during an immunodiagnostic assay. Additionally, the lamotrigine analogs can be used in immunodiagnostic assays to compete with lamotrigine for binding with anti-lamotrigine antibodies.
    Type: Grant
    Filed: January 25, 2010
    Date of Patent: November 26, 2013
    Assignee: Seradyn, Inc.
    Inventors: Anlong Ouyang, Lili Arabshahi, Mark Roberts, Melissa Wall
  • Publication number: 20130295101
    Abstract: Disclosed herein ricin toxin A chain polypeptides having an engineered disulfide bond ((SS)RTA) and compositions thereof. The disclosed (SS)RTA polypeptides retain the immunological epitope of wild type RTA, lack detectable N-glycosidase activity or exhibit reduced N-glycosidase activity as compared to controls, and exhibit increased solubility, thermal stability and a lower tendency to self-aggregate as compared to RTA 198 and/or RTA 1-33/44-198. Also disclosed are immunogenic compositions that may be used to immunize a subject against ricin intoxication. Methods of immunizing against, treating, inhibiting, reducing and/and preventing ricin intoxication are disclosed.
    Type: Application
    Filed: April 21, 2011
    Publication date: November 7, 2013
    Inventors: Patricia M. Legler, Jaimee R. Compton, Charles B. Millard, Mark A. Olson
  • Publication number: 20130243767
    Abstract: A molecule or molecule complex capable of binding to TLR9 and to CD32 comprising at least one epitope of at least one antigen, and its use a medicament for the treatment of allergies.
    Type: Application
    Filed: March 8, 2013
    Publication date: September 19, 2013
    Inventor: Geert Mudde
  • Publication number: 20130245241
    Abstract: Novel conjugates and immunogens derived from risperidone and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of risperidone and paliperidone in biological fluids.
    Type: Application
    Filed: April 30, 2013
    Publication date: September 19, 2013
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Daniel J. Cline, Howard Sard, Vishnumurthy Hegde
  • Publication number: 20130236491
    Abstract: A novel type of particle platform for application in biotechnology is provided by the present invention. Said platforms comprise RNA-free particles generated by thermal denaturation and structural remodeling of helical plant viruses. Tobamovir-uses and, in particular, tobacco mosaic virus (TMV) coat protein (CP) subunits, denatured, at high temperatures are specifically self-assembled by two-stage assembly into the spherical particles (SPs) of similar shape and varying size including nanoparticles (SNPs) with a diameter up to 100-150 nm and spherical microparticles (SMPs) with a diameter up to 800 nm and more. The size of said SPs depends on the virus concentration used and, therefore can be controlled. Said SPs are biologically safe, highly stable and highly immunogenic. Said SNPs and SMPs are structurally distinct from viruses presently known. They are unique, having no protein nano-particle analogs in the nature.
    Type: Application
    Filed: February 15, 2011
    Publication date: September 12, 2013
    Inventors: Iosif Grigorievich Atabekov, Olga Viacheslavovna Karpova, Mikhail Petrovich Kirpichnikov, Nikolay Alexandrovich Nikitin, Sergey Nikolaevich Chirkov, Ekaterina Alexeevna Trifonova, Anna Alexandrovna Sheveleva, Marina Vladimirovna Archipenko
  • Publication number: 20130183378
    Abstract: An immunogen includes an isolated peptide of 800 amino acid residues or fewer having the amino sequence ILSAFSVYV (SEQ ID NO:1) with four or fewer amino acid substitutions, a superagonist variant of SEQ ID NO:1, or an amino acid sequence having the formula: (I/K/T/V/M)-L-(S/L)-(A/E/N/D/Q)-(F/V)-(S/M/V/I)-(V/D/R/G/H)-Y-(V/I/L) (SEQ ID NO:13). The immunogens can be used in compositions and in the treatment of disorders.
    Type: Application
    Filed: March 14, 2013
    Publication date: July 18, 2013
    Inventor: Cedars-Sinai Medical Center
  • Patent number: 8481048
    Abstract: Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazine-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: July 9, 2013
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health
    Inventors: Rachel Schneerson, Joanna Kubler-Kielb, Fathy Majadly, Stephen H. Leppla, John B. Robbins, Darrell T. Liu, Joseph Shiloach
  • Publication number: 20130143296
    Abstract: The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody with a first binding site for a disease-associated antigen and a hapten on a targetable construct; b) administering a targetable construct comprising at least one therapeutic agent. In preferred embodiments, the bispecific antibody is made by the dock-and-lock (DNL) technique. In a more preferred embodiment, the targetable construct comprises one or more SN-38 moieties.
    Type: Application
    Filed: December 11, 2012
    Publication date: June 6, 2013
    Applicant: IMMUNOMEDICS, INC.
    Inventor: IMMUNOMEDICS, INC.
  • Publication number: 20130129777
    Abstract: Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against Plasmodium falciparum, the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine against Plasmodium vivax are also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.
    Type: Application
    Filed: January 25, 2013
    Publication date: May 23, 2013
    Applicant: The United States of America as represented by the Secretary, Department of Health and Human Service
    Inventor: The United States of America as represented by the Secretary, Department of Health and Human Services
  • Patent number: 8435800
    Abstract: The present invention relates in general to labeling reagents useful for labeling biomolecules. In particular, the invention provides activated labeling reagents having the formula L-Ph, wherein L is an activated labeling molecule and Ph is a phenol. The invention further provides methods of preparing the labeling reagents, methods of using the labeling reagents for synthesizing a labeled biomolecule, kits that include reagents for labeling a biomolecule and kits containing labeled biomolecules.
    Type: Grant
    Filed: November 22, 2005
    Date of Patent: May 7, 2013
    Assignee: BioSight Ltd.
    Inventor: Stela Gengrinovitch
  • Patent number: 8431416
    Abstract: Chemically-reactive, water-soluble, heterocycle-substituted 7-hydroxycoumarin dyes, their bioconjugates and uses are described. The conjugates derived from reactive heterocycle-substituted 7-hydroxycoumarin dyes are used for analyzing biological compounds. These heterocycle-substituted 7-hydroxycoumarin dyes are particularly useful as fluorescent labels for biopolymer detection reagents, such as antibodies or nucleic acid probes. The dye-antibody conjugates of the invention are particularly useful for analyzing analytes using a flow cytometer equipped with a violet laser as an excitation source due to their strong absorption at 405 nm and high fluorescence quantum yield.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: April 30, 2013
    Assignee: Becton, Dickinson and Company
    Inventors: Zhenjun Diwu, Timothy Dubrovsky, Barnaby Abrams, Jinfang Liao, Qinglin Meng
  • Publication number: 20130101613
    Abstract: The invention relates to a composition comprising at least two protective proteins against Streptococcus agalactiae (S. agalactiae) or functionally active variant thereof; a protective peptide against S. agalactiae; one or more nucleic acid(s) encoding the at least two proteins and/or the protective peptide; a method of producing the composition; a pharmaceutical composition, especially a vaccine, comprising the composition and/or at least one protective peptide; methods for producing antibodies; a mixture of antibodies against the at least two proteins of the composition; the use of the composition and/or at least one protective peptide and/or one or more nucleic acid(s) for the manufacture of a medicament for the immunization or treatment of a subject; methods of diagnosing a S.
    Type: Application
    Filed: November 26, 2012
    Publication date: April 25, 2013
    Applicant: Intercell AG
    Inventor: Intercell AG
  • Publication number: 20130052216
    Abstract: The present invention provides particle-forming chimeric proteins comprising a Calicivirus capsid protein and one or more heterologous antigen sequences. In particular, the present invention discloses engineered Calicivirus capsid protein sequences containing heterologous epitopes fused at internal locations such that the modified capsid proteins retain the ability to form virus-like particles when expressed in host cells. Virus-like particles comprising the chimeric proteins and vaccine formulations are also described.
    Type: Application
    Filed: January 21, 2011
    Publication date: February 28, 2013
    Inventors: Bryan Steadman, Ross Taylor
  • Publication number: 20130022544
    Abstract: The present invention is directed to polymerized products and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.
    Type: Application
    Filed: July 16, 2012
    Publication date: January 24, 2013
    Inventors: Thomas M. Wisniewski, Fernando Goni
  • Publication number: 20130011432
    Abstract: The invention is directed to an adenovirus-antigen conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus, as well as a conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus. The invention also provides a method of inducing an immune response against an antigen in a human using the aforementioned conjugates. The invention further provides an adeno-associated viral vector comprising a nucleic acid sequence which encodes an antibody directed against cocaine.
    Type: Application
    Filed: March 17, 2011
    Publication date: January 10, 2013
    Inventors: Ronald G. Crystal, Bishnu De, Martin Hicks, Jonathan Rosenberg, Stephen M. Kaminsky
  • Publication number: 20120329998
    Abstract: Provided is luminescent gold nanomaterial functionalized by N-(4-aminobutyl)-N-ethylisoluminol, methods of preparation and application thereof. The functionalized gold nanoparticle nanomaterial are formed by N-(4-aminobutyl)-N-ethylisoluminol bonding to the surface of the gold nanomaterial. The functionalized gold nanomaterial are prepared by directly reducing chloroauric acid with N-(4-aminobutyl)-N-ethylisoluminol, wherein N-(4-aminobutyl)-N-ethylisoluminol acts as reducer and stabilizer simultaneously. The preparation method is simple, fast and no need of special conditions. The preparation methods can be performed in a wide temperature range, for example, 15-35° C. The size and pattern of the functionalized gold nanomaterial can be specified by choosing the ratio of chloroauric acid to N-(4-aminobutyl)-N-ethylisoluminol. The obtained functionalized nano gold particles exhibit excellent chemiluminescence properties.
    Type: Application
    Filed: July 8, 2010
    Publication date: December 27, 2012
    Inventors: Hua Cui, Dayong Tian
  • Publication number: 20120328646
    Abstract: An immunogenic composition containing a glycan conjugate including a carrier protein, and a glycan including Globo H, an immunogenic fragment thereof, or stage-specific embryonic antigen-4 (SSEA-4), wherein the glycan is conjugated with the carrier protein through a linker.
    Type: Application
    Filed: August 7, 2012
    Publication date: December 27, 2012
    Applicant: Academia Sinica
    Inventors: Chi-Huey Wong, Chung-Yi Wu, Alice L. Yu, John Yu
  • Publication number: 20120329176
    Abstract: Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided.
    Type: Application
    Filed: August 31, 2012
    Publication date: December 27, 2012
    Inventors: Anthony S. Muerhoff, Suresh M. Desai, Thomas P. Leary, George J. Dawson, Robin A. Gutierrez
  • Publication number: 20120321659
    Abstract: This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and/or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them.
    Type: Application
    Filed: April 26, 2012
    Publication date: December 20, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventor: Kenneth Murray
  • Publication number: 20120294881
    Abstract: The present invention relates to a protective peptide of Streptococcus pneumoniae (S. pneumoniae) or a functionally active variant thereof; a composition comprising at least two of such peptides or variants; one or more nucleic acid(s) encoding such peptide or variant; a pharmaceutical composition comprising such peptide or variant, composition, or nucleic acid(s); a method of producing an antibody using such peptide or variant or composition; the use of such peptide or variant and/or composition and/or nucleic acid(s) for the manufacture of a medicament; a method of diagnosing a S. pneumoniae infection using such peptide or variant, composition or a primer and/or probe specific for the nucleic acid(s); a method for identifying a ligand capable of binding to such peptide or variant; and the use of such peptide or variant for the isolation, purification and/or identification of an interaction partner of the peptide.
    Type: Application
    Filed: August 3, 2012
    Publication date: November 22, 2012
    Applicant: Intercell AG
    Inventors: Andreas Meinke, Astrid Teubenbacher, Beatrice Tschanun, Manuel Zerbs, Markus Hanner, Jutta Pikalo, Eszter Nagy, Carmen Giefing-Kröll, Alexander Von Gabain
  • Publication number: 20120294877
    Abstract: The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines.
    Type: Application
    Filed: August 3, 2012
    Publication date: November 22, 2012
    Applicant: Oncotherapy Science, Inc.
    Inventors: Hideaki Tahara, Takuya Tsunoda, Masabumi Shibuya, Shuichi Nakatsuru
  • Publication number: 20120282292
    Abstract: Embodiments of the invention are directed to fibrillar adjuvants. Epitopes assembled into nanofibers by a short synthetic fibrillization domain elicited high antibody titers in the absence of any adjuvant.
    Type: Application
    Filed: November 19, 2010
    Publication date: November 8, 2012
    Applicant: University of Chicago
    Inventors: Joel H. Collier, Jai Simha Rudra